Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05452889 · ClinicalTrials.gov registry record · Early Phase 1
PET Image in PAH Patients
A Early Phase 1 study of Pulmonary Arterial Hypertension, sponsored by Stephen Y. Chan.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 71
- Enrollment target
- 1
- Study location
NCT05452889 is a Early Phase 1 study of Pulmonary Arterial Hypertension that is actively recruiting participants, run by Stephen Y. Chan. The registered enrollment target is 71 participants, below the 461-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05452889, a Early Phase 1 study of Pulmonary Arterial Hypertension, is actively recruiting participants, sponsored by Stephen Y. Chan.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
Pulmonary arterial hypertension (PAH) is mortal disease affecting the blood vessels of the lung. Despite its morbid prognosis, PAH is often misdiagnosed or ignored, with an average time of 44 months between onset of symptoms to diagnosis and substantial progression of disease severity. Therefore, a pressing need exists to develop non-invasive diagnostic imaging tools, particularly that can detect early disease stages. Efforts have been made to develop such imaging capabilities through platform development of echocardiography, cardiac MRI, chest computed tomography (CT), and positron emission tomography (PET), among others. While some have demonstrated promise, few have shown a precise ability to offer disease quantifications of the diseased lung and vasculature itself, to detect early stages of disease, and to reflect alterations of the lung, vasculature, and right ventricle that reflect the molecular origins of this disease. \[F-18\]FGln has been previously utilized in oncology studies as a non-invasive in vivo imaging biomarker of tumor glutamine flux and metabolism. Our preliminary in vivo pre-clinical rodent studies demonstrated that \[F-18\]FGln demonstrated increased uptake in diseased pulmonary vessels and the right ventricle in a rodent model of PAH. The proposed research study will provide preliminary evidence of the potential to utilize \[F-18\]FGln as a non-invasive imaging biomarker of glutamine flux and metabolism across a range of PAH subjects.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 18F-FGLN PET Imaging
- DRUG (18F)FPGLU
Study Locations (1)
Pennsylvania
- Montefiore Hospital Clinical and Translational Research Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2022-07-11 |
| Est. Completion | 2027-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05452889
The ClinicalTrials.gov registry entry for NCT05452889 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 461-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (85% lower). The listed sponsor is Stephen Y. Chan, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which 18F-FGLN PET Imaging is the first listed.
NCT05452889 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05452889 about?
NCT05452889 is a clinical study titled "PET Image in PAH Patients". Pulmonary arterial hypertension (PAH) is mortal disease affecting the blood vessels of the lung. Despite its morbid prognosis, PAH is often misdiagnosed or ignored, with an average time of 44 months between onset of symptoms to diagnosis and substantial progression of disease severity. Therefore, a ...
What is the current status of trial NCT05452889?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 71 participants. The study started on 2022-07-11. Estimated completion is 2027-02.
What conditions does trial NCT05452889 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT05452889?
The interventions under investigation include: 18F-FGLN PET Imaging (DIAGNOSTIC_TEST), (18F)FPGLU (DRUG).
Who is sponsoring clinical trial NCT05452889?
This trial is sponsored by Stephen Y. Chan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05452889 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
RECRUITING · NA
-
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
RECRUITING · Phase 3
-
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.